A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins
- PMID: 8663426
- DOI: 10.1074/jbc.271.30.17644
A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins
Abstract
Germ line mutations of the ret proto-oncogene are associated with the development of three dominantly inherited neoplastic disorders, multiple endocrine neoplasia (MEN) 2A, MEN 2B, and familial medullary thyroid carcinoma. It has been demonstrated that the mutations result in constitutive activation of the Ret protein, leading to transformation of NIH 3T3 cells. In the present study we investigated the role of tyrosine residues present in the carboxyl-terminal sequence for the transforming activity of Ret with the MEN 2A or MEN 2B mutation (MEN2A-Ret or MEN2B-Ret). Substitution of phenylalanine for tyrosine 1062 (designated Y1062F) markedly impaired the transforming activity of both MEN2A-Ret and MEN2B-Ret, whereas substitution or deletion for four other tyrosines (codons 981, 1015, 1090, and 1096) did not affect their activity. The Shc adaptor proteins bound to the MEN2A-Ret and MEN2B-Ret proteins and were phosphorylated on tyrosine in the transfectants. The binding of Shc to the Y1062F mutant proteins was reduced by approximately 80%, indicating that tyrosine 1062 is a major binding site for Shc. In addition, phosphopeptide analysis of MEN2A-Ret demonstrated that tyrosine 1062 represents an autophosphorylation site of the mutant Ret proteins.
Similar articles
-
Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.Cancer Res. 2001 Feb 15;61(4):1426-31. Cancer Res. 2001. PMID: 11245446
-
Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.Oncogene. 1996 Feb 1;12(3):481-7. Oncogene. 1996. PMID: 8637703
-
Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.Cancer Res. 2000 Sep 15;60(18):5254-60. Cancer Res. 2000. PMID: 11016655
-
[From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].Ned Tijdschr Geneeskd. 2001 Nov 17;145(46):2217-21. Ned Tijdschr Geneeskd. 2001. PMID: 11757244 Review. Dutch.
-
Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations.Recent Results Cancer Res. 1998;154:229-36. doi: 10.1007/978-3-642-46870-4_14. Recent Results Cancer Res. 1998. PMID: 10027003 Review.
Cited by
-
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.J Pers Med. 2023 Jul 13;13(7):1132. doi: 10.3390/jpm13071132. J Pers Med. 2023. PMID: 37511745 Free PMC article. Review.
-
Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical.Molecules. 2023 Jun 9;28(12):4672. doi: 10.3390/molecules28124672. Molecules. 2023. PMID: 37375228 Free PMC article. Review.
-
FOXA2 and STAT5A regulate oncogenic activity of KIF5B-RET fusion.Am J Cancer Res. 2023 Feb 15;13(2):638-653. eCollection 2023. Am J Cancer Res. 2023. PMID: 36895965 Free PMC article.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
RET receptor signaling: Function in development, metabolic disease, and cancer.Proc Jpn Acad Ser B Phys Biol Sci. 2022;98(3):112-125. doi: 10.2183/pjab.98.008. Proc Jpn Acad Ser B Phys Biol Sci. 2022. PMID: 35283407 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous
